Russell2000 News & Analysis
4 articles
Market Mood
Russell 2000 Surges 20% in 2026, Best Year Since 2003
The Russell 2000 index has increased by 20% in 2026, marking its best performance since 2003. Unprofitable companies within this index have risen 154% since mid-2025, outpacing profitable firms that gained 34%. As investors prioritize AI exposure over current earnings, this trend highlights a shift in market dynamics. The index's performance contrasts with the S&P 500's 11% rise and the 4% growth of major tech stocks. This matters for ordinary investors as it signals a new opportunity to explore small-cap stocks benefiting from AI infrastructure investments.
Read More: Russell 2000 Surges 20% in 2026, Best Year Since 2003
AtaiBeckley (ATAI) Included in Russell Indices Effective June 29
AtaiBeckley N.V. (NASDAQ: ATAI) announced on June 25 that it will be included in the Russell 2000 and Russell 3000 indices starting June 29. This reconstitution is significant as over $12 trillion in assets are tied to these benchmarks. Following this news, Canaccord Genuity raised its price target for ATAI from $15 to $17, indicating an upside potential of over 227%. The company is also advancing towards Phase 3 development for major depressive disorder after concluding dosing for its Phase 2 Elumina trial. This inclusion in major indices could enhance visibility and trading volume for ATAI shares, impacting investor interest.
Read More: AtaiBeckley (ATAI) Included in Russell Indices Effective June 29
Investing in Underperforming Trades for Strong Returns Ahead
ETFs focused on underperforming sectors may yield significant returns in the next six months, according to ETF Action co-founder Mike Akins. He highlights software and cloud computing stocks as areas to boost exposure, referencing the 'Magnificent Seven' index comprising Nvidia, Microsoft, Alphabet, Amazon, Meta, Apple (AAPL), and Tesla (TSLA). This group fell over 2% year-to-date, while the Nasdaq-100 rose nearly 20%, though the Magnificent Seven has gained 5% recently. The Russell 2000, tracking small-cap stocks, is up almost 20% this year, suggesting emerging opportunities for investors.
Read More: Investing in Underperforming Trades for Strong Returns Ahead
Madison Fund Sold Globus Medical (GMED) as Valuation Exceeded
Madison Small Cap Fund liquidated its position in Globus Medical, Inc. (GMED) after a multi-year investment, citing a market cap increase to $12 billion and a share price of $90 compared to their intrinsic value estimate of $85. GMED shares closed at $80.52 on June 11, 2026, with a one-month return of 5.06% and a 36.71% increase over the past year. For Q1 2026, GMED reported revenue of $759.9 million, reflecting a year-over-year growth of 27%. Despite its potential, the fund expressed a preference for smaller investment alternatives amid AI stock opportunities.
Read More: Madison Fund Sold Globus Medical (GMED) as Valuation Exceeded